NCT07938580
Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percentage of Participants Achieving an Anemia Response
Timeframe: 24 week
Secondary (12)
Percentage of Participants With a Sustained Increase in Mean Hemoglobin of at Least 1.0 g/dL Without Transfusion
Time to Anemia Response
Duration of Anemia Response
Change From Baseline in Red Blood Cell Transfusion Amount and Frequency
Change From Baseline in Hemoglobin
Show 7 moreShow less
SVR35
DoMSR
MPN-SAF TSS
Reduction in Fatigue Score
Adverse Events
PFS
OS
Arms and interventions
Gecacitinib + LuspaterceptExperimental
gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks
Drugs: Gecacitinib, Luspatercept